Good news too on Zantac.17 May 2023 23:12
As a retired litigation lawyer I am really comforted by the continued failure of litigants here against GSK.
Most if not all of these litigants will have been taken on 'no win no fee' and with a number of class actions now dismissed,
legal firms must be getting the wind up. Especially comforting was the last dismissal because it was by a Judge in Canada, not USA,
The sp does not reflect the way this cookie is crumbling. Without the Zantac litigation and with the number and extent of new FDA successes, my opinion is that GSK is far too cheap and at present a prime candidate for a takeover fight at £20 or more.